Agile Therapeutics Inc. is an early-stage biopharmaceutical company focused on the development of novel transdermal products addressing women's health. The company is targeting three markets with its hormonal patch products: contraception, hormone replacement therapy, and gynecologic diseases. Agile Therapeutics's lead product is a 7-day transdermal contraceptive patch, combining levonorgestrel (LNG), a synthetic progestin, with ethinyl estradiol (EE), a synthetic estrogen. The product utilizes breakthrough technology that enables the delivery of LNG/EE at sufficient levels to provide effective contraception in a patch of reasonable size. Results of the phase II trial demonstrated that the levels of LNG and EE were sufficient to prevent conception.